ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
Sep 22, 2026
DALLAS - Sept. 22, 2026 - PRLog -- ClearSight Therapeutics, Inc. Receives NIH SBIR Phase I Award for Research in Acute Infectious Conjunctivitis and EKC
Competitive federal award provides external scientific validation of the proposed research program and funds a disciplined path to new evidence
DALLAS, September 22nd, 2026 - ClearSight Therapeutics, Inc., a Dallas-based eye-care company, today announced that it has received a $306,852 Small Business Innovation Research Phase I award from the National Eye Institute, part of the National Institutes of Health. The competitive award marks a major scientific milestone for ClearSight and supports a one-year investigational research program involving a preservative-free ophthalmic formulation in acute infectious conjunctivitis and epidemic keratoconjunctivitis.
The project, award number R43EY039140, runs from September 15, 2026 through August 31, 2027. ClearSight Chief Scientific Officer Nuria Jimenez, PhD, PMP, will serve as principal investigator. The Notice of Award identifies the project as research and development and states that it does not support an NIH-defined clinical trial.
Why this award matters
NIH funding decisions follow rigorous peer review of scientific and technical merit and a second-level assessment of mission relevance. Reviewers consider the importance of the proposed research, the rigor and feasibility of the approach, and whether the investigators and organization have the expertise and resources to carry out the work. For ClearSight, the award provides meaningful external validation of the proposed scientific program and creates an accountable path for turning a promising research premise into credible evidence. It does not predetermine the results; it makes the disciplined work to generate those results possible.
"This award is a defining milestone for ClearSight. Following competitive review of the scientific and technical merit of our proposed work, NIH support gives us both meaningful external validation and non-dilutive capital to build the evidence base with rigor. It is a powerful vote of confidence in the importance of the question, the strength of the research plan, and our team's ability to execute."
Patrick Smale, Co-founder and Chief Executive Officer
"The questions at the center of this program matter to patients, clinicians, and the broader eye-care community. NIH support gives us the opportunity to investigate them with the rigor they deserve, generate credible data, and let the evidence guide what comes next. I am proud to lead this work alongside our team and collaborators."
Nuria Jimenez, PhD, PMP, Chief Scientific Officer and Principal Investigator
"I am excited and grateful for this initial support from the National Eye Institute, which represents an important step in advancing our innovation toward clinical development. This funding will enable us to generate the rigorous data needed to further validate the technology and its potential to address important unmet needs in topical ocular therapy. As a co-inventor and drug developer, I am particularly encouraged by the opportunity to translate this innovation into a product where patient safety, efficacy, and meaningful clinical benefit remain our highest priorities."
Suchismita Acharya, PhD, Co-Founder, Co-Inventor and Board Member
The SBIR program supports research and development by eligible small businesses. Beyond providing non-dilutive capital, the award gives ClearSight a structured milestone period through August 2027 and an accountable framework for translating a scientific premise into data. The work will proceed under a defined research plan, milestones, and federal reporting obligations.
Important regulatory context
ClearSight's NIH-funded research program will study preservative-free ophthalmic formulation in acute infectious conjunctivitis and EKC. This investigational research is separate from the labeled uses of any OTC lubricant eye drop marketed under M018 and does not establish safety, efficacy, or regulatory approval for treating either condition.
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas-based eye-care company founded in 2023 by industry veterans to develop accessible solutions for common ocular conditions. The company maintains distinct commercial and research programs, including OTC lubricant development under applicable monograph labeling and separately described investigational research. Learn more at clearsighttx.com.
NIH funding acknowledgment
Research reported in this release is supported by the National Eye Institute of the National Institutes of Health under Award Number R43EY039140. A total of $306,852, or 100% of the project, is financed with federal funds. A total of $0, or 0%, is financed with non-governmental funds. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Media contact
Patrick Smale
Co-founder & CEO
ClearSight Therapeutics
[email protected]
972-983-7761
Photos: (Click photo to enlarge)
Source: ClearSight Therapeutics, Inc.
Read Full Story - ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research | More news from this source
Press release distribution by PRLog
More News
Senate Democrats press Trump administration on consumer refunds after tariff ruling
A group of Senate Democrats, joined by independent Sen. Bernie Sanders (Vt.), are pressing U.S. Trade Representative Jamieson Greer over tariffs refunds following a Supreme Court decision earlier this year that ruled certain Trump administration tariffs were illegal. The letter, signed by Sens. Elizabeth Warren (D-Mass.), Martin Heinrich (D-N.M.), Sheldon Whitehouse (D-R.I.), Richard Blumenthal (D-Conn.),...
What are Flock cameras, other ALPRs looking for?
You may have noticed more ALPRs around you. Here's what they're looking for.
Trump says AI will be renamed 'super intelligence' in all US documents
President Trump told the United Nations General Assembly on Tuesday that artificial intelligence will be renamed “super intelligence” in all U.S. documents. “The United States also totally rejects any attempt to construct a globality scheme to control for the artificial intelligence being spoken of so much now, hereinafter called super intelligence. Changing the name,” Trump...
Tourists rescued from Oregon beach after spelling ‘SOS’ with driftwood
The Netarts-Oceanside Fire District shared photos of the visitors who became stranded on Lost Boy Beach in a post on Facebook, showing the SOS sign.
Katie Porter weighs in on billionaire tax: 'Perpetuates the status quo'
(Nexstar) — Two months after swearing off politics, former California gubernatorial candidate Katie Porter is back in the fray — sort of. Porter, who finished in a distant 5th place in this year's primary, said in July that she was "done, for now, with politics." The former lawmaker also called the change a "new chapter...
How Unions Are Confronting A.I. Threats in the Workplace
The machinists union shows how workers are negotiating for a say in the ways artificial intelligence is used in their workplaces.
Trump defends Iran war, touts ‘America is back’ agenda in UN speech
US President Donald Trump addressed the global community on Tuesday morning with a speech before the UN General Assembly that sought to justify his war with Iran, touted how he has “made peace” and argued that his “make America great again” policies benefited the world. His speech came as the world grapples with years of conflict in Ukraine, Iran, Gaza, Sudan, Yemen and Lebanon, with no relief in sight. “I can report to you with pride that America is back, and our country is stronger today than...
Learning from Ukraine war, Chinese military doctors target injuries from drones
China’s military medical experts are making progress in finding cures for common injuries seen in drone warfare, drawing on lessons from the wars in Ukraine and the Middle East, according to state broadcaster CCTV. Chen Juxiang, a senior Chinese military doctor, told CCTV on Monday that cranio-maxillofacial injuries – damage to the hard and soft tissues of the head – had become a particularly big problem in conflicts dominated by drones. Chen, director of neurosurgery at the First Affiliated...
2 pilots killed in firefighting helicopter crash near Yosemite
One of the pilots was Greg King, who used to work for the Alaska Division of Forestry and Fire Protection and fought several wildland fires in that state.
China names new Tibet party chief as Communist Party reshuffles regional leadership
Beijing has appointed a new party chief in Tibet as the Communist Party shuffles regional leaders ahead of its 21st national congress. Hu Changsheng, 62, will serve as the party secretary of Tibet autonomous region, leaving his post as party secretary of Gansu province to Wu Xiaojun, 60, currently the party chief of Qinghai province. Meanwhile, Luo Dongchuan, 60, Qinghai’s governor, will succeed Wu as party secretary of the province. The 21st party congress is expected to be held next year and...
Hong Kong workforce to shrink by 20,000 yearly as key sectors face shortages
Hong Kong’s workforce is forecast to shrink by around 20,000 a year until 2028 despite measures to import labour and talent, with shortages remaining most acute among skilled technical workers. A government report on manpower projections on Tuesday found that although the labour shortfall would narrow to 130,000 by 2028, down by nearly a third from the original estimate of 180,000, the city would continue to face critical manpower challenges across key sectors. “Due to economic transformation,...
O'Reilly: 'Republicans can't survive the anger that people are feeling' on spending
Political commentator Bill O’Reilly on Monday said Republicans cannot survive the anger people are feeling about the ongoing affordability crisis ahead of the 2026 midterm elections. Appearing on NewsNation, host Leland Vittert asked O’Reilly if remarks made by Republican candidates in battleground elections who are calling for an end to the Iran war as grocery...
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.